OmniAb to Participate at the Leerink Partners Global Healthcare Conference

OmniAb, Inc. (NASDAQ: OABI) has announced that its management team will participate in the upcoming Leerink Global Healthcare Conference, which is scheduled to take place from March 8-11, 2026, in Miami, specifically at the W South Beach hotel. During this prominent event, the company will present a corporate overview on Tuesday, March 10, at 3:40 p.m. Eastern Time. Additionally, OmniAb will offer the opportunity for one-on-one meetings with investors registered for the conference, facilitating direct engagement with potential stakeholders. Interested investors are encouraged to arrange meetings through their Leerink Partners representative or by reaching out via email.

OmniAb is renowned for its innovative discovery research technology, which it licenses to a variety of pharmaceutical and biotech firms as well as academic organizations. This technology is integral in helping partners uncover next-generation therapeutics. Central to OmniAb’s platform is its proprietary Biological Intelligence™, which empowers engineered transgenic animals to produce optimized antibody candidates for human therapeutic applications. The company prides itself on the diversity of its animal host systems, which represent the most varied options available in the industry.

The OmniAb business model is designed to address critical challenges in drug development by providing integrated and customizable solutions. Their robust suite of technological methods includes computational antigen design, advanced immunization strategies, and high-throughput screening techniques, which work together to deliver fully-human antibodies with excellent performance characteristics. Through structured agreements that incorporate access fees, service revenues, milestones, and royalties on commercial sales, OmniAb effectively aligns its scientific and economic interests with those of its partners. For more information, visit [OmniAb's website](www.omniab.com).

OmniAb, Inc. (NASDAQ: OABI) is set to make an appearance at the Leerink Partners Global Healthcare Conference from March 8-11, 2026. This presents a timely opportunity for investors to closely observe the company's corporate developments and strategic direction. Scheduled for a presentation on March 10 at 3:40 p.m. Eastern time, management will outline its business model centered on a unique antibody discovery technology—a significant draw for potential and current investors.

The company's platform focuses on generating optimized antibody candidates through advanced methodologies, such as high-throughput screenings and next-generation sequencing analysis. Given the rising demand for novel therapeutics in the biotech space, OmniAb’s capacity to license its technology to pharmaceutical companies and academic institutions is a critical element that sets it apart from competitors. For investors, understanding this vital role in drug development is essential, as it aligns with market trends emphasizing personalized and targeted therapies.

With a diversified income stream from upfront fees, royalties, and milestone payments, OmniAb's business model reflects a balanced approach to risk management and revenue generation. This should assure investors of its potential for stable growth, especially as the market for biopharmaceuticals continues to expand.

Investors are encouraged to engage with management during the conference for a more in-depth discussion on operational strategies and potential partnerships. This interaction not only provides insight into financial forecasts but also enhances understanding of the competitive landscape OmniAb operates in.

In summary, participation at the Leerink conference is an important event for OmniAb. Investors would do well to monitor developments closely, as advancements in their technology and strategic partnerships could lead to substantial long-term investment returns.